Curis Amends its Existing Collaboration with Aurigene for the Development and Commercialization of CA-170
Shots:
- Aurigene to fund and conduct P-IIb/III study assessing CA-170 + chemoradiation in ~240 patients with nsq. NSCLC and get exclusive rights to develop and commercialize CA-170 in Asia in addition to its existing rights in India and Russia- as per its previous agreement
- Curis will retain the right to develop & commercialize CA-170 in the US- EU and ROW and will receive royalties on sales of the therapy in Asia
- CA-170 (PO) is a dual inhibitor of VISTA and PDL1- being evaluated in P-IIa basket study- demonstrated efficacy in patients with nsq. NSCLC
Click here to read full press release/ article | Ref: PRNewswire | Image: Just Dial
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
